Click Here for Frequently Asked Questions about MCO-010 and to Join Our Mailing List for Future Updates

Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.

Latest News from Nanoscope

Press Release: October 10, 2024

Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa

READ COMPLETE PRESS RELEASE

Press Release: September 12, 2024

Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration

READ COMPLETE PRESS RELEASE

Jeff, a patient in our STARLIGHT Clinical Trial for Stargardt Macular Degeneration began to experience vision loss as a young boy. Today, Jeff is seeing more of the world and feeling positive about the future.

Roy, a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa began to experience vision loss 20 years ago. After MCO-010 treatment Roy saw colors he had not seen in years and is now determined to participate in all aspects of his community.

Richard, a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa, talks about the changes MCO-010 treatment has made in his life.

Hear how John, a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa feels about his experience two years after being enrolled in the study.

Hear what a Stargardt Macular Degeneration patient in our STARLIGHT Clinical Trial has to say about her experience.

Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.

Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.

LEARN ABOUT OUR TECHNOLOGY

Our lead gene therapy product in clinical trials for retinitis pigmentosa will be the first therapy to correct the condition and is applicable for patients with complete or partial degeneration of the retina.

Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration

LEARN MORE ABOUT OUR PIPELINE

Nanoscope News & Events

READ ALL NANOSCOPE NEWS & EVENTS
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.